Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its shares have held stable, even touching $30 per share. SanaCurrents, which tracks market-moving catalysts of biopharmaceutical